New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSomatropin (HGH) vs Chonluten

Somatropin (HGH) vs Chonluten

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)
Anti-Aging & Longevity
Chonluten
Summary
Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Half-Life
2-3 hours (subcutaneous); 20-30 minutes (intravenous)
Short (minutes for the peptide); sustained gene-regulatory effects
Admin Route
Subcutaneous, Intramuscular (less common)
SubQ, Oral
Research
Typical Dose
0.15-0.3 mg/day (adults); titrated to IGF-1 levels
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Increases lean muscle mass and reduces body fat (particularly visceral)
  • Restores growth hormone deficiency (FDA-approved)
  • Improves bone mineral density
  • Enhances exercise capacity and recovery
  • Supports skin thickness and collagen synthesis
  • Improves lipid profile in GHD patients
  • Explored for anti-aging and cellular regeneration
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
Side Effects
  • Fluid retention and edema (common, dose-dependent)
  • Carpal tunnel syndrome
  • Joint and muscle pain
  • Insulin resistance and elevated blood glucose
  • +3 more
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
Stacks With